1. Introduction {#sec1}
===============

Liver failure is a severe clinical syndrome characterized by hepatic encephalopathy, jaundice, coagulopathy, and a high mortality rate. Hepatitis viruses, drugs, or toxins can precipitate acute liver failure in patients with or without chronic liver disease \[[@B1]\]. Unfortunately, liver transplantation currently remains the only definitive treatment option for irreversible liver failure \[[@B2]\]. Approximately 90% of patients are cured after liver transplantation \[[@B3], [@B4]\], but there is a serious shortfall of donors, especially in China, and costs are considerable for many families. Some patients recover spontaneously with standard medical therapy.

Artificial liver support systems (ALSSs) are a bridge to liver transplantation or recovery after liver failure and are useful means of improving biochemical parameters and clinical symptoms \[[@B5]\]. An ALSS is an external support system that can remove several types of harmful substances while supplementing essential substances, thereby improving the internal environment and create conditions for the regeneration of liver cells and restoration of liver function. There are various modalities connecting treatment units either in series or in parallel such as plasma exchange (PE) combined with hemofiltration (HF), molecular absorbent recirculatory systems, fractionated plasma separation and absorption (using the Prometheus system), and double plasma molecular absorption systems (DPMAS).

The safety of most ALSS devices has been well established by clinical studies \[[@B2]\]. Commonly reported side effects of ALSSs include filter clotting, leukocytosis, hypotension, bleeding, anaphylaxis, and thrombocytopenia \[[@B2]\]. A vasovagal reaction (VVR) is an abnormal autonomic imbalance precipitated by pain, hunger, heat, imagined or real exposure to bodily harm, certain medical and surgical procedures, cardiac spasm, distention of viscera, and pleural or peritoneal irritation, which is characterized by hypotension followed by paradoxical bradycardia \[[@B6]\]. More seriously, strong vagal stimulation may lead to arrhythmias, syncope, transient asystole, seizures, or death \[[@B7]--[@B10]\]. To the best of our knowledge, a VVR during ALSS treatment has not been reported previously. Here, we describe 18 patients who experienced a VVR during treatment with an ALSS.

2. Material and Methods {#sec2}
=======================

2.1. Patients {#sec2.1}
-------------

We retrospectively reviewed the medical records of patients who underwent ALSS treatment for liver failure at our hospital and suffered an ALSS-related VVR from January 1, 2018 to June 30, 2019.

A VVR was defined as the presence of at least one of the following criteria with associated symptoms: (1) bradycardic episode (heart rate (HR) \< 60 beats/min (bpm)) and hypotension (systolic blood pressure (SBP) \< 100 mmHg) in the supine position or (2) development of syncope \[[@B6], [@B11]\]. Common symptoms include pallor, faintness, dizziness, sweating, nausea, shivering, vomiting, heat intolerance, cold intolerance, and loss of consciousness \[[@B12]\]. Exclusion criteria were heart failure, myocardial infarction, or other severe liver diseases. A VVR was noted only if the reaction occurred following the entire procedure, including femoral vein catheter placement.

2.2. Data Collection {#sec2.2}
--------------------

Data collected at the time of ALSS treatment included age, sex, body mass index, etiology of liver failure, serum total bilirubin (TB) level, alanine and aspartate aminotransferase (ALT, AST) levels, glucose level, and international normalized ratio (INR). The diastolic blood pressure (DBP), SBP, and HR after extracorporeal circulation were used as the baseline data. When a VVR occurred, the onset time, minimum BP and HR, symptoms, treatment measures, and recovery time were all recorded in detail.

2.3. ALSS Treatment {#sec2.3}
-------------------

The indications for ALSS treatment were based on the Chinese Guideline for Diagnosis and Treatment of Liver Failure \[[@B13]\] and include (1) early- or intermediate-stage acute, subacute, and acute-on-chronic liver failure (prothrombin activity of 20--40%); (2) end-stage liver disease awaiting liver transplantation; (3) rejection after liver transplantation or a nonfunctional transplanted liver; and (4) severe cholestasis (TB \> 10 mg/dL) due to ineffective medical treatment. PE combined with HF was administered to five patients. PE was performed for 2 h each time using the EC-40 W plasma separator (Asahi Kasei, Japan), and the replacement fluid contained 500--1,000 mL albumin plus 1,500--2,000 mL fresh frozen plasma, for a total exchange volume of 2,500--3,000 mL. Subsequently, HF was performed continuously for approximately 4--6 h using the BLS816G (SORIN Group, Italy) at a filtrate flow rate of 50 mL/kg/h. The entire procedure lasted 6--8 h. A DPMAS was used to treat 13 patients. The plasma was separated using the EC-40 W device (Asahi Kasei), purified by an anion exchange resin column (HA330-II, Jian Fan, China) and a bilirubin adsorption column (BS330, Jian Fan), and finally returned to the patient. ALSS treatment was administered using the IQ21 machine (Asahi Kasei). A double-lumen catheter was inserted into the femoral vein to obtain vascular access. Heparin was given to prevent coagulation, with the dosage adjusted based on the transmembrane pressure and activated partial thromboplastin time. A plasma allergy was prevented by administering 5 mg dexamethasone before ALSS treatment.

2.4. Statistical Analysis {#sec2.4}
-------------------------

Data were compared using Student\'s *t*-test conducted in Prism, version 8.0.0 (GraphPad, San Diego, CA). Statistical significance was defined at *P* \< 0.05.

3. Results {#sec3}
==========

Among 637 patients who underwent ALSS treatment, a VVR occurred in 18 (2.82%), who were included in the study. The clinical features of the 18 patients (9 males and 9 females) are shown in [Table 1](#tab1){ref-type="table"}. The mean age of the patients was 53.2 (range 22--74) years, and the mean body mass index was 21 (range 18--28) kg/m^2^; excluding patient 17 who was too weak to obtain height or weight data. The most common etiology of liver failure was hepatitis B virus (56%), followed by drugs (22%). The glucose levels in all patients were normal to high (range 6.7--16.8 mmol/L) at the time of the VVR. All patients exhibited increased aminotransferase levels: the ALT level ranged from 39 to 427 (mean 138) U/L and the AST level from 34 to 383 (mean 129) U/L. Jaundice was present in all 18 patients. The serum TB level ranged from 175 to 583 (mean 358) *μ*mol/L. In five patients, coagulation dysfunction was present, with an INR level ≥ 1.5 (the peak INR level was 2.78 in patient 15).

Detailed information on ALSS treatment and the VRRs, including modality of ALSS, VVR duration, changes in HR and BP, and treatment provided for the VVR, are listed in [Table 2](#tab2){ref-type="table"}. Of the 18 patients, 13 (72%) were managed using a DPMAS, and the remaining 5 (28%) received PE combined with HF. The majority of patients (78%) suffered a VVR during their first ALSS treatment. Sixteen patients experienced the relevant symptoms after treatment commenced and the onset time of VVR ranged from 10 to 100 min. Only two patients experienced symptoms during femoral vein catheter placement. The VVR was associated with significant changes in BP and HR. The mean basal and minimum HR were 80 and 52 bpm, respectively, and the mean basal and minimum SBP were 119 and 72 mmHg, respectively. Trends in HR and mean arterial pressure are described in [Figure 1](#fig1){ref-type="fig"}. Dizziness, sweating, nausea, and chest distress were frequently reported by these patients.

During treatment, most patients (89%) received human albumin or Ringer\'s solution to increase the circulating blood volume. Atropine, as an effective drug for blocking a VVR, was used in more than half of the patients (61%). Six patients received dopamine with or without aramine. The VVR duration was short (\<20 min) in 15 patients and more than 20 min in 3 patients, ranging from 3 to 105 min. The VVR time of onset and duration in all 18 patients are shown in [Figure 2](#fig2){ref-type="fig"}.

4. Discussion {#sec4}
=============

We detected an incidence of a VVR occurring during ALSS treatment of 2.82%. There are no previously published data on VVR incidence for comparison with our results. It is important differentiate VVR from hypoglycemia. VVR is a rare complication of ALSS treatment and is more frequently associated with spine procedures \[[@B14]\], blood donation \[[@B15]\], cerebral angiography via femoral catheterization \[[@B11]\], and percutaneous coronary intervention \[[@B16]\]. In the general blood donor population, the VVR rate was reported to be 1.4%. VVR during spinal injection was found to be a common adverse event, with a rate of 0--8.6. \[[@B14]\] As for PE treatments, it was reported that the VVR rate was about 0.5%, in which the patients were diagnosed with the Guillain-Barre syndrome, myasthenia gravis, and so on, but liver injury were not included \[[@B17]\]. Compared with other conditions, a VVR incidence of 2.82% may be considered moderate.

In the present study, all patients during the VVR experienced a remarkable decrease in BP or HR accompanied by symptoms such as dizziness and sweating. Symptoms and signs returned to normal within 3--105 min, which is similar to the duration (from several minutes to 2 h) reported in a study of VVR associated with cerebral angiography \[[@B11]\]. Sixteen (89%) instances of VVR occurred during normal ALSS treatment, ranging from 10 to 100 min after treatment commenced. The remaining two instances of VVR occurred during femoral vein catheter placement. In a study on VVR occurring during blood donation \[[@B18]\], 54.4% of VVR episodes occurred during blood collection, 28.6% after collection and 9.8% after entering the refreshment area; 1.4% occurred even later, after the donor had left the site. In addition, 5.9% of VVR incidents was associated with blood test procedures requiring venipuncture. In short, VVR occurred before, during, and after blood collection, whereas ALSS-related VVR occurred mainly before and during ALSS treatment.

The vagus nerve runs throughout the vascular endothelial system. Physiologically, a VVR is believed to be caused by the initial increase in BP and HR due to an adrenergic response, followed by overcompensation by a sudden withdrawal of sympathetic tone and increased parasympathetic tone, resulting in splanchnic vasodilation, bradycardia, and decreased cerebral blood flow \[[@B19]\]. Hypermetabolism in the adrenal gland responsible for synthesizing and secreting catecholamines is indicated by increased adrenal fluorodeoxyglucose accumulation on positron emission tomography/computed tomography \[[@B20]\]. Elements such as fear, pain, and a bad mood can be triggers, leading to a strong autonomic response \[[@B12]\]. Internal factors such as hyperventilation, hypotension, and stress may also precipitate a VVR in some cases \[[@B21]\]. Alcohol ingestion may predispose individuals to a VVR in the clinical setting \[[@B22]\].

Patients require femoral vein catheter placement before ALSS treatment. Two patients experienced a VVR during this procedure. As reported by other studies, patients who received a vascular interventional examination or therapy were more likely to develop a VVR, which was commonly seen at the time of sheath placement \[[@B11]\]. A poor response to intraoperative local anesthesia, which may increase the patient\'s pain sensitivity, and stimulation of the vascular intima by a guide wire or catheter both can cause enhanced excitability of the vascular vagus nerve. On the other hand, patient anxiety or even insomnia may stimulate the pressure transducers in the left ventricle and carotid artery, leading to enhanced vagus nerve excitability \[[@B11]\]. When treatment begins, a portion of the blood flows into the pipeline, which results in relative hypovolemia, similar in some respects to blood donation. In patients with liver failure, toxins typically accumulate in the blood vessels to cause an attenuated vasoconstrictor response. As a result, mobilization of the peripheral venous blood and net fluid absorption from tissues to blood decrease \[[@B23]\].

VVR is an unexpected high-risk condition that may cause irreversible harm including arrhythmias, syncope, myocardial infarction, transient asystole, and seizures even death to patients without timely treatment \[[@B7]--[@B10], [@B24]\]. Most patients who develop VVR could recover after timely and accurate treatment in previous study \[[@B6]\], the same as we have observed. In our 18 patients, therapy for symptomatic hypotension and bradycardia was administered according to the judgement of the clinician. The treatment measures included stopping the pump of the machine, change in position (supine position with the head turned to one side or the Trendelenburg position), and fluid infusion. The final measure was intravenous injection of atropine, dopamine, aramine, or adrenaline. All patients recovered after timely and appropriate treatment. According to our experience and a literature review, we devised a suggested treatment algorithm. First, operation of the ALSS device should be stopped to reduce stimulation and prevent a further reduction of the circulating blood volume. The patient\'s anxiety should be assuaged by reassurance and "talk-esthesia." \[[@B12]\] Second, reclining the patient rapidly into the Trendelenburg position helps facilitate perfusion to the brain \[[@B25]\]. Hand holding will help increase peripheral resistance and venous return \[[@B26]\]. Third, sufficient fluid infusion is essential. Human albumin and Ringer\'s solution are optional. If these measures are ineffective, 0.5 mg atropine should be injected intravenously at an appropriate dosage to reverse vagal cardiac stimulation. If the BP drops markedly, dopamine and aramine should be used. If asystole occurs, the emergency activation system should be initiated.

In an ALSS treatment setting, these steps can be taken to minimize the risk of a VVR as much as possible. It has been reported that during blood donation, the fear of drawing blood was associated with an approximately threefold increase in the odds of experiencing a VVR \[[@B27]\]. Thus, humanistic concern and psychological counseling are beneficial. Before treatment, clinicians should explain the entire ALSS procedure and related complications to the patient in detail to eliminate their fear and anxiety. The support of a family member or trusted friend is integral \[[@B12]\]. Patients should be encouraged to eat regularly and drink adequate fluids while avoiding alcohol before treatment \[[@B12]\]. At the time of femoral vein catheter placement, sufficient local anesthesia may reduce pain stimulation \[[@B16]\]. During ALSS treatment, medical personnel can communicate with the patient to create a nonthreatening and relaxing environment. Furthermore, the BP, HR, and subjective symptoms of the patient should be closely monitored, since early discovery and treatment of VVR can prevent severe outcomes.

The present study has some limitations. In this retrospective analysis, the data were collected in a strict prospective manner utilizing electronic medical records. The number of cases was limited. Furthermore, data following catheter removal were unavailable. A larger-scale prospective study is required to validate our findings.

5. Conclusions {#sec5}
==============

To conclude, a VVR is a rare complication that can occur before or during ALSS treatment for liver failure, including during catheter placement. Clinicians should be aware of the possibility of a VVR and take the appropriate measures to prevent its occurrence.
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###### 

Clinical characteristics of 18 cases of ALSS-associated VVR.

  Variable     Age (years)   Sex      BMI (kg/m^2^)   Etiology of liver injury   Glu (mmol/L)   ALT (U/L)   AST (U/L)   TBil (*μ*mol/L)   INR
  ------------ ------------- -------- --------------- -------------------------- -------------- ----------- ----------- ----------------- ------
  Patient 1    49            Male     23              Hepatitis B virus          9.7            57          135         583               2.15
  Patient 2    62            Female   24              Hepatitis B virus          13.4           53          69          529               1.47
  Patient 3    71            Male     21              Mixed                      16.8           427         243         283               2.71
  Patient 4    50            Female   19              Drugs                      8.1            79          74          337               0.96
  Patient 5    53            Male     21              Hepatitis B virus          7.8            183         74          202               0.92
  Patient 6    59            Female   19              Cholestasis                10.2           425         383         366               1.19
  Patient 7    73            Female   18              Drugs                      14.9           213         249         175               0.92
  Patient 8    54            Male     21              Hepatitis B virus          14.2           91          93          332               1.48
  Patient 9    59            Female   21              Drugs                      8.9            124         214         254               1.64
  Patient 10   69            Female   22              Drugs                      9.3            54          34          353               0.97
  Patient 11   27            Male     19              Hepatitis B virus          8.7            97          89          372               1.41
  Patient 12   62            Female   18              Cholestasis                12.4           151         69          333               1.12
  Patient 13   44            Male     21              Hepatitis B virus          9.7            39          58          322               1.16
  Patient 14   22            Male     23              Hepatitis B virus          6.7            77          94          401               1.3
  Patient 15   74            Female   21              Hepatitis B virus          10.8           60          59          322               2.78
  Patient 16   26            Male     28              Hepatitis B virus          9              113         165         548               1.49
  Patient 17   67            Female   Unavailable     Mixed                      11.6           92          133         398               2.68
  Patient 18   37            Male     26              Hepatitis B virus          8.5            146         82          341               1.9

Note. ALSS: artificial liver support system; VVR: vasovagal reaction; BMI: body mass index; ALT: alanine aminotransferase; AST: aspartate aminotransferase; TBil: total bilirubin; INR: international normalized ratio; Glu: glucose.

###### 

Detailed procedural features of ALSS and VVR.

        Baseline   Minimum                                                                                                                                                   
  ----- ---------- --------- --------------------------------------- ----------------------- ----- ----- ---- ---- ---- ---- ----------------------------------------------- --------------------------------------------------------------------------------------
  P1    PE+CRRT    1         30 minutes                              7 minutes               81    100   64   60   78   44   Chest distress, waist discomfort                Dopamine 0.8 mg, aramine 0.4 mg, Ringer\'s solution
  P2    DPMAS      1         30 minutes                              10 minutes              53    114   61   30   61   44   Chest distress, nausea, dizziness, yawning      Adrenaline 0.04 mg, human albumin, Ringer\'s solution
  P3    PE+CRRT    1         31 minutes                              7 minutes               101   156   90   57   74   45   Yawning, waist discomfort, defecation           Human albumin
  P4    DPMAS      3         63 minutes                              17 minutes              70    108   70   41   85   45   Abdominal distension                            Atropine 0.5 mg, dopamine 3 mg, Ringer\'s solution
  P5    DPMAS      1         During catheter placement, 20 minutes   5 minutes, 70 minutes   78    109   64   40   76   47   Nervousness                                     Atropine 0.25 mg, Ringer\'s solution
  P6    DPMAS      1         49 minutes                              10 minutes              70    102   56   49   58   33   Palpitation, sweating                           Atropine 0.5 mg, Ringer\'s solution
  P7    DPMAS      1         20 minutes                              10 minutes              85    109   67   50   56   31   Chest distress, nausea, dizziness               Dopamine 20 mg, human albumin
  P8    DPMAS      1         34 minutes                              5 minutes               61    124   79   36   79   42   Chest distress                                  Atropine 0.5 mg
  P9    DPMAS      1         30 minutes                              30 minutes              74    120   68   35   67   45   Chest distress, nausea, dizziness               Atropine 0.5 mg, dopamine 20 mg, Ringer\'s solution
  P10   DPMAS      1         40 minutes                              3 minutes               70    132   68   42   52   31   Chest distress                                  Atropine 0.5 mg, Ringer\'s solution
  P11   DPMAS      3         56 minutes                              5 minutes               80    120   70   49   83   39   Abdominal pain                                  Atropine 0.5 mg, Ringer\'s solution
  P12   DPMAS      2         100 minutes                             5 minutes               54    142   72   38   72   40   Urination, abdominal distension                 Atropine 0.5 mg, Ringer\'s solution, dopamine 20 mg, human albumin
  P13   DPMAS      1         63 minutes                              9 minutes               89    119   82   62   79   44   Abdominal discomfort, nausea                    Human albumin
  P14   DPMAS      1         50 minutes                              15 minutes              80    107   69   60   89   42   Dizziness, tinnitus                             Ringer\'s solution
  P15   PE+CRRT    3         10 minutes                              10 minutes              70    125   72   50   79   49   Sore back                                       Human albumin, Ringer\'s solution
  P16   DPMAS      1         10 minutes                              40 minutes              114   114   78   83   63   36   Chest distress, palpitation, nausea, vomiting   Dexamethasone 3 mg, atropine 0.5 mg, dopamine 6 mg, aramine 3 mg, Ringer\'s solution
  P17   PE+CRRT    1         15 minutes                              11 minutes              120   112   57   98   67   38   Yawning, dry mouth                              Atropine 0.25 mg
  P18   Li-ALS     1         During catheter placement               8 minutes               84    135   86   57   75   35   Nervousness, chest distress, dizziness          Atropine 0.5 mg, Ringer\'s solution

Note. ALSS: artificial liver support system; VVR: vasovagal reaction; PE: plasma exchange; CRRT: continuous renal replacement therapy; DPMAS: double plasma molecular absorb system; Li-ALS: Li\'s artificial liver system; HR: heart rate; SBP: systolic blood pressure; DBP: diastolic blood pressure.
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